Scientists test new combo attack on stubborn blood cancers

NCT ID NCT02568553

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested a new combination of two drugs, lenalidomide and blinatumomab, for people with non-Hodgkin lymphoma that had come back or stopped responding to other treatments. The main goal was to find the safest and most effective dose of the drugs when used together. Researchers also looked at whether the treatment could shrink the cancer and how it affected the patients' immune systems.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Johns Hopkins University/Sidney Kimmel Cancer Center

Baltimore, Maryland, 21287, United States
Keck Medical Center of USC Pasadena

Pasadena, California, 91105, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Northside Hospital

Atlanta, Georgia, 30342, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
UC San Diego Moores Cancer Center

La Jolla, California, 92093, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390, United States
University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, 35233, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States
Wayne State University/Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Yale University

New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.